The Latest

Newest Abortion Restrictions May Affect HIV Screening and Care

Creating stigma for abortions may have a chilling effect on those seeking any sexual health care.

By Martha Kempner

Pressure Mounts on Truvada PrEP Pricing With Lawsuit and Congressional Hearings

"This isn't about you," Rep. Alexandria Ocasio-Cortez (D-NY) told Gilead CEO Daniel O'Day. "We have legislated a system that allows [this] to happen."

By Tim Murphy

Will Recent Gilead Patent Concessions on Truvada Lower PrEP Prices?

Activists say this relatively small giveaway won't advance PrEP access or help end HIV in the U.S. the way a true price reduction would.

By Tim Murphy

Advocates Navigate Tricky Political Terrain for Federal HIV Funding to End the U.S. Epidemic

An alliance of advocacy groups called The Partnership rallies Congress for funding while rejecting most Trump administration policies impacting the HIV community.

By Kenyon Farrow

How Activists Uncovered CDC's Ownership of Truvada PrEP Patents

The #PrEP4All campaign made the call for affordable pre-exposure prophylaxis a national news story.

By Charles Sanchez

If Nobody Slashes the Price of Truvada for PrEP, What Happens Next?

Activists and doctors say they're ready to go further if Gilead won't agree to -- or the U.S. government won't force -- a price reduction to make PrEP accessible to more Americans who need it.

By Tim Murphy

Sticker Shock: PrEP Is Not Cost-Effective at Current Price, Health Economists Find

But a survey reveals that about a third of black and Latino gay men would be willing to pay more than $50 per month for a prescription.

By Sony Salzman

PrEP Pricing Is the Elephant in the Room at the CDC National HIV Prevention Conference

In a debate during a plenary session, Michael Saag, M.D., argued for more activism to make PrEP accessible to people who need it.

By Sony Salzman

The Trump Administration's Drug Pricing Proposals for People With HIV, Explained

Drug pricing expert Tim Horn helps us make sense of the administration's future plans for the Medicare Part D and 340B programs.

By Tim Murphy

In the Battle to Control Drug Costs, Old Patent Laws Get New Life

Patients' rights activists and health industry's big players are usually at odds with each other, but now they are championing similar tactics to tame prescription drug prices.

By Shefali Luthra for Henry J. Kaiser Family Foundation